Wir sind mit live! Mehr erfahren

Relmada Therapeutics

RLMD

Börsenwert 331 Mio. $

3,10 USD

-0,10

3,13 %

Zum Börsenschluss Aktualisiert 16. Okt., 16:00 EDT

1 Tag

-3,13 %

5 Tage

-8,55 %

1 Monat

-26,54 %

3 Monate

-43,22 %

6 Monate

-55,71 %

Seit Jahresbeginn

-29,06 %

1 Jahr

54,23 %

5 Jahre

-86,57 %

10 Jahre

-71,72 %

Profil: Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.

Mitarbeiter: 17

Gesundheitswesen Biotechnologie

Nachrichten

Positiv

Neutral

Negativ

Stimmung 3 Monate

Positiv 37,5 %

Neutral 50 %

Negativ 12,5 %

Zacks Investment Research

5 Small Drug Stocks Poised to Benefit From a Biotech Recovery

INDV, IRWD, RLMD, LRMR and CRDL could offer significant upside as biotech sentiment improves, backed by catalysts and differentiated pipelines.

5 Small Drug Stocks Poised to Benefit From a Biotech Recovery

Relmada Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference

CORAL GABLES, Fla., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced that senior management will participate in one-on-one meetings at the Wells Fargo 21st Annual Healthcare Conference being held in Boston, MA, from September 8 - 10, 2026.

Relmada Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference

Zacks Investment Research

After Plunging 18.5% in 4 Weeks, Here's Why the Trend Might Reverse for Relmada Therapeutics (RLMD)

Relmada Therapeutics (RLMD) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

After Plunging 18.5% in 4 Weeks, Here's Why the Trend Might Reverse for Relmada Therapeutics (RLMD)

Zacks Investment Research

Here's Why Relmada Therapeutics (RLMD) Is a Great 'Buy the Bottom' Stock Now

Relmada Therapeutics (RLMD) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Here's Why Relmada Therapeutics (RLMD) Is a Great 'Buy the Bottom' Stock Now

Zacks Investment Research

Down 29.6% in 4 Weeks, Here's Why Relmada Therapeutics (RLMD) Looks Ripe for a Turnaround

Relmada Therapeutics (RLMD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Down 29.6% in 4 Weeks, Here's Why Relmada Therapeutics (RLMD) Looks Ripe for a Turnaround

Relmada Therapeutics Q2 Earnings Call Highlights

Relmada Therapeutics NASDAQ: RLMD said it is prioritizing manufacturing activities for NDV-01, its sustained-release intravesical formulation of gemcitabine and docetaxel for non-muscle invasive bladder cancer, as it targets an investigational new drug application filing by the end of 2026.

Relmada Therapeutics Q2 Earnings Call Highlights

Relmada Therapeutics, Inc. (RLMD) Q2 2026 Earnings Call Transcript

Relmada Therapeutics, Inc. (RLMD) Q2 2026 Earnings Call Transcript

Relmada Therapeutics, Inc. (RLMD) Q2 2026 Earnings Call Transcript

Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer

CORAL GABLES, Fla., July 28, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced the appointment of Bipin Dalmia, PhD, MBA, as Chief Business Officer. Bipin will lead Relmada's corporate strategy, commercial planning, and business development activities, reporting directly to Chief Executive Officer Sergio Traversa.

Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer

Relmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026

CORAL GABLES, Fla., July 16, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced plans to host a conference call and webcast on Thursday, August 6, 2026 at 4:30 PM ET to discuss financial results for the second quarter ended June 30, 2026, and recent business progress.

Relmada Therapeutics to Report Second Quarter 2026 Financial Results on Thursday, August 6, 2026

Relmada Therapeutics Joins Russell 2000® and Russell 3000® Indexes

CORAL GABLES, Fla., June 29, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today announced that the Company joined the Russell 2000® Index and the Russell 3000® Index effective after the U.S. market closed on June 26, 2026, as part of the Russell Indexes reconstitution.

Relmada Therapeutics Joins Russell 2000® and Russell 3000® Indexes

Nachrichtenrankings ansehen

Kursdiagramme mit Lightweight Charts™ umgesetzt